Top Value Stocks For 2018

Heading into the most crucial (and dangerous) time of the year for Florida-based property insurance firms, Universal Insurance Holdings (NYSEMKT:UVE) is looking stronger than ever.

First Quarter Earnings

UVE continued its strong year-over-year growth trend when it reported its first quarter earnings:

Continuing Growth Trend – Revenue grew 6.3% year over year, and Universal Direct premiums written grew 7.7% (4.3% in Florida and 44.9% growth elsewhere). The growth trend is especially encouraging because it indicates the company is diversifying away from Florida, helping to secure its profitability against the possibility of destructive Florida hurricanes. As part of this diversifying growth push, the company obtained its Certificate of Authority from Iowa, pushing its licensed total to 19 states. Improving Profitability – Despite $3 million weather losses beyond plan in the quarter, the net combined ratio declined year over year due to a lower expense ratio. Meanwhile, the company continued to achieve high returns on equity (over 30%). Earnings Growth – Net income grew by 23.7% and diluted EPS grew by 21.7%. Strengthening Balance Sheet – Book value per share grew a remarkable 7.4% during the quarter and 25.9% year over year while the company maintained minimal debt, a strong and steady investment portfolio, and a conservative cash reserve.

Reinsurance Program

Top Value Stocks For 2018: Ishares Trust Dj Us Financial (IYF)

Advisors’ Opinion:

  • [By Wayne Duggan]

    Investors looking to set up a pair trade to capitalize on the divergent paths of U.S. and European banks should consider going long the iShares Dow Jones US Financial (ETF) (NYSE: IYF) and short the Ishares MSCI Europe Fincls Sctr Indx Fd (NASDAQ: EUFN).

Top Value Stocks For 2018: iShares Nasdaq Biotechnology Index Fund(IBB)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Of course, Donald Trump took on the health care industry in his press conference today, so Gilead’s shares–and just about every other biotech and pharmaceutical company–are getting smacked down. Its stock fallen 2.4% to $25.03 at 3:30 p.m. today, while the iShares Nasdaq Biotechnology ETF (IBB) has fallen 2.9% to$278.49.

  • [By Craig Jones]

    Guy Adami believes that iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) is a Buy. He explained that it held well in a tough trading session for the rest of the market.

  • [By ]

    After sneaking lower to begin the new trading week, the SPDR S&P Biotech ETF (NYSE:XBI) and the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) were each approaching important support levels.

  • [By ]

    The SPDR S&P Biotech ETF (NYSE:XBI) and the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) were each approaching important support levels back in mid-November.

  • [By ]

    October was not kind to the biggest names in biotech. While smaller, more speculative biotech names consolidated, the big kids fell off a cliff. The biotech slide accelerated midway through the month, with both the large-cap iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) and the smaller SPDR S&P Biotech ETF slipping more than 5%.

Top Value Stocks For 2018: iShares Core S&P Mid-Cap (IJH)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of Lubar & Co., Inc’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Lubar+%26+Co.%2C+Inc

    These are the top 5 holdings of Lubar & Co., IncEnLink Midstream LLC (ENLC) – 1,882,007 shares, 37.97% of the total portfolio. Shares added by 0.40%Hallador Energy Co (HNRG) – 2,788,685 shares, 23.23% of the total portfolio. Vanguard Value ETF – DNQ (VTV) – 77,126 shares, 7.65% of the total portfolio. iShares Core S&P Mid-Cap (IJH) – 38,400 shares, 6.84% of the total portfolio. New PositionVanguard Mid-Cap Value ETF – DNQ (VOE) – 61,550 shares, 6.52% of the tota

Top Value Stocks For 2018: Stag Industrial, Inc.(STAG)

Advisors’ Opinion:

  • [By Lee Jackson]

    STAG Industrial Inc. (NYSE: STAG) offers investors a 5.8% yield. Share recently traded hands at $24.35 apiece, in a 52-week range of $22.42 to $28.85. The consensus target price is $27.73.

Leave a Reply

Your email address will not be published. Required fields are marked *